Daraxonrasib (Rasonque): FDA Approves First-in-Class Multi-Selective RAS Inhibitor for Metastatic Pancreatic Cancer

The Pancreatic Cancer Burden: Why This Approval Matters

Pancreatic cancer has long represented one of oncology's most intractable challenges. Approximately 67,000 Americans are diagnosed annually, and more than half present with metastatic disease at the time of diagnosis. The five-year survival rate for metastatic pancreatic adenocarcinoma remains approximately 3% — a figure that has barely shifted in three decades despite incremental advances in chemotherapy combinations.

Second-line systemic therapy options have been particularly limited. After progression on frontline gemcitabine/nab-paclitaxel or FOLFIRINOX, median overall survival with available chemotherapy regimens has historically ranged from 4.4 to 6.7 months, with response rates below 15% and unacceptably high discontinuation due to toxicity. The clinical situation has been described, accurately, as a medical emergency at the population level.

The molecular driver of this disease has been known for decades: over 90% of pancreatic adenocarcinomas carry mutations in KRAS, predominantly at codons G12 and G13. These mutations lock RAS in its GTP-bound, active (oncogenic) state — driving proliferation, evasion of apoptosis, and resistance to therapy. For over 40 years, mutant KRAS was considered "undruggable," until the first KRAS G12C inhibitors (sotorasib, adagrasib) reached the clinic in lung cancer. But KRAS G12C accounts for fewer than 2% of pancreatic adenocarcinomas, leaving the vast majority of patients without a targeted option.

Today's FDA approval of daraxonrasib changes that calculus fundamentally.

Mechanism of Action: RAS(ON) Multi-Selective Inhibition

Daraxonrasib (formerly RMC-6236) is a first-in-class RAS(ON) multi-selective inhibitor, developed by Revolution Medicines, Inc. (Redwood City, CA). Unlike the earlier generation of KRAS inhibitors that target only the GDP-bound (inactive) state of specific KRAS variants, daraxonrasib binds the GTP-bound (active, "ON") conformation of RAS — the very state responsible for oncogenic signaling.

This broad activity profile is what separates daraxonrasib from the KRAS G12C inhibitors: it is not a single-variant inhibitor constrained by a specific cysteine target. The drug is administered orally, once daily, as a tablet — a meaningful convenience advantage in the palliative setting.

RASolute 302: Phase 3 Trial Design

The approval is supported by data from RASolute 302 (NCT06625320), a randomized, open-label, Phase 3 trial conducted across sites in North America, Europe, and Asia. The trial enrolled 500 patients with metastatic pancreatic adenocarcinoma who had received at least one prior line of systemic therapy.

Patients were randomized 1:1 to receive either daraxonrasib (oral, once daily) or physician's choice of chemotherapy (commonly nanoliposomal irinotecan + 5-FU/leucovorin or oxaliplatin-based regimens). The primary endpoint was overall survival in patients with RAS G12 variant tumors, with secondary endpoints including PFS, ORR, and OS in the overall population. Biomarker testing for RAS mutation status was performed centrally but was not required for trial entry — patients with wild-type RAS were enrolled in the overall population analysis.

Efficacy Results

RASolute 302 met its primary endpoint at the pre-specified interim analysis. The results were described by investigators as unprecedented for second-line pancreatic cancer.

The near-doubling of median overall survival — from 6.7 to 13.2 months — represents the largest single improvement in second-line pancreatic adenocarcinoma OS ever reported in a Phase 3 trial. The magnitude of the PFS benefit (7.2 vs 3.6 months overall) and the tripling of objective response rate (31.6% vs 11.2%) are similarly without precedent in this setting.

Safety and Tolerability

The safety profile of daraxonrasib is an important part of the clinical story. In a population with advanced pancreatic cancer who typically experience significant disease-related symptom burden, the tolerability of second-line therapy is a major determinant of quality of life and treatment duration.

Grade ≥3 adverse events occurred in 43.6% of daraxonrasib patients versus 57.5% on chemotherapy — a statistically and clinically meaningful difference. Most striking is the discontinuation rate: only 1.2% of daraxonrasib patients discontinued due to adverse events, compared with 11.2% in the chemotherapy arm.

The superior tolerability profile of daraxonrasib versus chemotherapy is clinically meaningful: the 10-percentage-point difference in Grade ≥3 events, and the 9-fold lower discontinuation rate, suggest patients on daraxonrasib are substantially more likely to remain on therapy and thus to derive maximum benefit from the survival advantage demonstrated in the trial.

Regulatory Pathway and Designations

The regulatory history of daraxonrasib reflects the FDA's accelerated approach to high-priority oncology approvals. The approval on August 26, 2026 came 6.5 months ahead of the Prescription Drug User Fee Act (PDUFA) target date — an unusual acceleration that underscores the FDA's assessment of the drug's clinical significance.

Approved Indication and Patient Population

The FDA-approved indication for daraxonrasib (Rasonque) is:

The dual eligibility criterion — progression after prior therapy OR ineligibility for multiagent chemotherapy — is clinically pragmatic. A substantial proportion of patients with metastatic pancreatic cancer are performance status-compromised at first progression and would historically have had limited options; this language extends access to those patients specifically.

Notably, the indication does not restrict use by RAS mutation status, despite the primary trial endpoint being RAS G12 variant patients. This reflects the efficacy demonstrated across the full population (OS 13.2 vs 6.7 months overall) and the mechanistic rationale for activity in RAS wild-type tumors as well.

Implications for Clinical Trials and Site Teams

For research sites currently enrolling or planning pancreatic cancer trials, the approval of daraxonrasib creates immediate practical considerations.

Standard of Care Shift in Second-Line PDAC

Daraxonrasib now becomes the anticipated new standard of care for second-line metastatic pancreatic adenocarcinoma in patients with RAS G12 mutations — covering approximately 90–95% of the eligible population. Protocol teams designing second-line studies must account for this when defining comparator arms. Chemotherapy as a control arm in second-line PDAC trials will now face scrutiny from IRBs and ethics committees given the established superior OS of a targeted alternative.

Companion Diagnostics and Biomarker Testing

Although the approved indication does not mandate RAS mutation testing, the magnitude of benefit in the RAS G12 subgroup makes routine molecular profiling standard practice. Clinical sites should review their tissue acquisition protocols and laboratory turnaround times for KRAS/RAS sequencing. Liquid biopsy (cell-free DNA) testing platforms capable of detecting G12D, G12V, and G12R mutations in real time will become increasingly important for treatment decisions at first progression.

Combination Therapy Trials

Revolution Medicines and academic collaborators are expected to pursue daraxonrasib-based combination strategies (with PD-1/PD-L1 inhibitors, EGFR inhibitors, and MEK pathway agents) in the post-approval period. Sites with established pancreatic cancer programs should anticipate sponsor outreach for combination expansion protocols in both first-line and earlier-line settings.

Real-World Data Collection

Given the 8.5-month median follow-up at the time of approval, longer-term survival data and real-world outcomes data will be critical. Sites treating patients with daraxonrasib should consider registry enrollment and structured outcomes reporting to contribute to post-marketing evidence generation.